Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Ugo Marchèse

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8647-7584; OpenAlex author ID A5059444864. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2019: 2 papers · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers · 2026: 3 papers

Papers 21

  1. Pancreatic ductal adenocarcinoma in IgG4-related disease. Last author DOI 10.1016/j.diii.2026.03.003↗
  2. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  3. Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomography. Co-author DOI 10.1177/08465371261426959↗
  4. Nationwide analysis of one-year mortality following pancreatectomy in 17,183 patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2024.10.011↗
  5. End-of-life care for patients with pancreatic cancer in France: a nationwide population-based cohort study. Co-author DOI 10.1177/17588359251320731↗
  6. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  7. [Hereditary and familial forms of pancreatic adenocarcinoma: Genetic determinism, patients eligible for systematic screening, screening methods and results]. Co-author DOI 10.1016/j.bulcan.2023.11.002↗
  8. Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.10.028↗
  9. Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. First author DOI 10.1177/08465371221124927↗
  10. Interobserver Variability and Accuracy of Preoperative CT and MRI in Pancreatic Ductal Adenocarcinoma Size Estimation: A Retrospective Cohort Study. Co-author DOI 10.1177/08465371221137885↗
  11. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Co-author DOI 10.3390/cancers14246179↗
  12. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity … Co-author DOI 10.1016/j.hpb.2021.04.003↗
  13. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  14. Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13133103↗
  15. Prospective Evaluation of Resection Margins Using Standardized Specimen Protocol Analysis among Patients with Distal Cholangiocarcinoma and Pancreatic Ductal A… Co-author DOI 10.3390/jcm10153247↗
  16. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Co-author DOI 10.1016/j.ejso.2020.02.037↗
  17. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.12.001↗
  18. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Co-author DOI 10.1186/s12885-020-6690-1↗
  19. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? Co-author DOI 10.1186/s12893-020-00835-3↗
  20. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement. Co-author DOI 10.1016/j.jviscsurg.2018.06.014↗
  21. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-019-1637-1↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maxime Barat · 6 shared papers, 2021–2026 · strength 1.39
  2. Jonathan Garnier · 9 shared papers, 2019–2025 · strength 1.06
  3. Jean‐Robert Delpéro · 9 shared papers, 2019–2021 · strength 1.03
  4. Olivıer Turrini · 9 shared papers, 2019–2021 · strength 1.03
  5. Philippe A. Soyer · 5 shared papers, 2021–2026 · strength 0.89
  6. Romain Coriat · 5 shared papers, 2021–2026 · strength 0.89
  7. Anna Pellat · 4 shared papers, 2022–2026 · strength 0.83
  8. Thị Thùy Linh Nguyễn · 2 shared papers, 2026 · strength 0.77
  9. Marine Gilabert · 7 shared papers, 2019–2021 · strength 0.76
  10. Flora Poizat · 6 shared papers, 2019–2021 · strength 0.67
  11. Mehdi El Amrani · 3 shared papers, 2025 · strength 0.62
  12. Alain Sauvanet Sauvanet · 3 shared papers, 2024–2025 · strength 0.54
  13. Laurent Boyer · 2 shared papers, 2025 · strength 0.46
  14. Marc F. Giovannini · 4 shared papers, 2019–2020 · strength 0.42
  15. Stéphanie Truant · 2 shared papers, 2025 · strength 0.39
  16. Sébastien Gaujoux · 2 shared papers, 2024–2025 · strength 0.34
  17. Laurence Moureau-Zabotto · 3 shared papers, 2019–2020 · strength 0.31
  18. Christophe Laurent · 2 shared papers, 2021–2025 · strength 0.28
  19. Marwa Alkatheeri · 1 shared paper, 2026 · strength 0.27
  20. Vinciane Rebours · 1 shared paper, 2024 · strength 0.20
  21. Einas Abou Ali · 1 shared paper, 2024 · strength 0.20
  22. David Malka · 1 shared paper, 2024 · strength 0.20
  23. Bruno Buecher · 1 shared paper, 2024 · strength 0.20
  24. Patrick Pessaux · 1 shared paper, 2024 · strength 0.18
  25. Gerlinde Avérous · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.